Zirconium-89 Radiopharmaceuticals: Current Status and Future

eczacilikbilimleri-1-2-2021

Elif Tuğçe SARCANa, A. Yekta ÖZERa

aHacettepe University, Faculty of Pharmacy, Department of Radiopharmacy, Ankara, TURKEY

ABSTRACT
Immuno-PET is a non-invasive imaging method that uses PET radionuclides and biomolecules in combination. Antibodies and monoclonal antibodies are among the most frequently used biomolecules with Immuno-PET. Recently, among the PET radionuclides commonly used with antibody/mAbs, the radiometals have a relatively long half-life compared to other radionuclides such as Zirconium-89(89Zr), Copper-64 (64Cu), Yttrium-86 (86Y) are seen. The Zirconium-89 radiometal is a popular research subject nowadays, and it is used in the radiolabelling of antibodies, monoclonal antibodies, nanoparticles and proteins due to their favourable half-life (3.3 days) and research in this sense continues. In this article, Zirconium-89 which has increased popularity in the last 10 years and is considered a suitable PET radionuclide for biomolecules due to its long half-life, is reviewed from production to radiolabelling methods; and use in Nuclear Medicine clinical trials and ongoing researchs. This review aims to briefly investigate Zirconium-89 radionuclide, which will probably find its value in the clinic in the near future and provide information about its current status.
Keywords: Zirconium-89; Zirconium-89 labelled antibody; monoclonal antibody

Referanslar

  1. Knowles Sm, Wu Am. Advances in immunopositron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-92. [Crossref]  [PubMed]  [PMC]
  2. Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;1:131-9. [Crossref]  [PubMed]  [PMC]
  3. Goldenberg Dm, Sharkey Rm. Advantages in cancer therapy with radiolabeled monoclonal antibodies. Q J Nuc med mol Imaging. 2006;50:248-64.
  4. marquez-Nostra bV, Viola N. The Radiopharmaceutical Chemistry of Zirconium-89. In: Lewis J, Windhorst A, Zeglis b, eds. Radiopharmaceutical Chemistry. Springer, Cham; 2019. [Crossref]
  5. Ikotun OE, Lapi SE. The rise of metal radionuclides in medical imaging: Copper-64, zirconium-89 and ytrium-86. Future med Chem. 2012;3:599-621. [Crossref]  [PubMed]
  6. Holland JP, Sheh YC, Lewis JS. Standardized methods for the production of high spesific-activitiy zirconium-89. Nucl med biol. 2009;36:729-39. [Crossref]  [PubMed]  [PMC]
  7. Verel I, Visser GW, boellaard R, Stigter-van Walsum m, Snow G, Van Dongen GA. 89Zr Immmuno- PET: comprehensive procedures fort he production of 89Zr-labeled monoclonal antibodies. J Nuc med. 2003;44:1271-81.
  8. Lubberink m, Herzog H. Quantitative Imaging of 124I and 86Y with PET. Eur J Nuc med mol Imag. 2011;38:10-8. [Crossref]  [PubMed]  [PMC]
  9. La mT, Tran VH, Kim HK. Progress of coordination and utilization of zirconium-89 for positron emission tomography (pet) studies. Nuc mEd mol Imag. 2019;53:115-24. [Crossref]  [PubMed]  [PMC]
  10. Larenkov A, bubenschikov V, makichyan A, Zhukova m, Krasnoperova A, Kodina G. Preparation of zirconium-89 solutions for radiopharmaceutical purposes: interrelation between formulation, radiochemical purity, stability and biodistribution. molecules. 2019;24:3-24. [Crossref]  [PubMed]  [PMC]
  11. van Dongen GAmS, Huisman mC, boellaard R, Hendrikse NH, Windhorst Ad, Visser GWm, et al. 89Zr-Immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl med mol Imaging. 2015;59:18-38.
  12. bhatt Nb, Pandya DN, Wadas TJ. Recent advances in zirconium-89 chelator development. molecules. 2018;23:1-24. [Crossref]  [PubMed]  [PMC]
  13. Natarajan A, Habte F, Gambhir. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized trangenic mouse model. bioconjugate Chemistry. 2012;23:1221-9. [Crossref]  [PubMed]  [PMC]
  14. Deri mA, Zeglis bm, Francesconi LC, Lewis JS. PET Imaging with 89Zr: from radiochemistry to the clinic. Nuc med biol. 2013;40:3-14. [Crossref]  [PubMed]  [PMC]
  15. Vugts DJ, Visser GW, van Dongen GA. 89ZrPET radiochemistry in the development and application on therapeutic monoclonal antibodies and other biologicals. Curr Topics in med Chem. 2013;13:446-57. [Crossref]  [PubMed]
  16. Perk L, Vosjan mWD, Visser GW, et al. Pisothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nuc med mol Imag. 2010;37:250-9. [Crossref]  [PubMed]  [PMC]
  17. Vosjan mJWD, Perk LR, Visser GWD, budde m, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocynatobenzyl-desferrioxamine. Natura Protocol. 2010; 5:729-43. [Crossref]  [PubMed]
  18. Lee FT, Scott Am. Immuno-PET for tumor targeting. J Nucl med. 2003;44:1282-3.
  19. Fischer G, Seibold U, Schirrmacher R, Wangler b, Wangler C. 89Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. molecules. 2013;18:6469-90. [Crossref]  [PubMed]  [PMC]
  20. Verel I, Visser GWm, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl med. 2005;46:164S-171S.
  21. Tang Y, Hu Y, Liu W, Zhao Y, ma H, et al. A Radiopharmaceutical [89Zr]-Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo. Nuc med biol. 2019;70:23- 31. [Crossref]  [PubMed]
  22. Poot AJ, Adamzek KWA, Windhorst AD, Vosjan mJWD, Kropf S, Wester H-J, van döngen GAmS, Vugts DJ. Fully automated zirconium89 LAbelling and purification of antibodies. J Nuc med. 2018;62:1-15. [Crossref]  [PubMed]
  23. Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama Em, et al. monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zrtrastuzumab PET. J Nuc med. 2013;54:936-43. [Crossref]  [PubMed]  [PMC]
  24. Rizvi SNF, Visser OJ, Vosjan mJWD, van Lingen A, Hoekstra OS, Zijlstra Jm, et al. biodistrubition, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed b-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl med mol Imaging. 2012;39:512- 20. [Crossref]  [PubMed]  [PMC]
  25. Börjesson PK, Jauw YW, boellaard, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-40. [Crossref]  [PubMed]
  26. Menke-van der Houven Oordt CW, Gootjes EC, Huisman mC, Vugts DJ, Roth C, Luik Am, mulder ER, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:30384-93. [Crossref]  [PubMed]  [PMC]
  27. Even AJG, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJL, Heukelom J, Tesselaar mET, bogel WV, et al. Quantitative assessment of zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget. 2017;8:3870- 80. [Crossref]  [PubMed]  [PMC]
  28. Dijkers EC, Oude munnink TH, Kosterink JG, brouwers AH, Jager PL, de Jong JR, van Dongen GA, et al. biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharm Therap. 2010;87:586-92. [Crossref]  [PubMed]
  29. Bruno R, Washington Cb, Lu J, Lieberman G, banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chem Pharm. 2005;56:361- 9. [Crossref]  [PubMed]
  30. Gaykema Sbm, brouwers AH, Hooge mNL, Pleijhuis Rg, Timmer-bosscha H, Pot L, van Dam Gm, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nuc med. 2013;54:1014-8. [Crossref]  [PubMed]
  31. van der Watering FCJ, Rijpkema m, Perk L, brinkmann U, Oyen WJG, boerman OC. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. biomed Res Int. 2014;2014:1-13. [Crossref]  [PubMed]  [PMC]
  32. Chang SS. Overwiev of prostate-spesific membrane antigen. Rev Urol.2004;6:13-8.
  33. Jauw YWS, menke-van der Houven van Oordy CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra Jm, et al. Immuno-positron emission tomography with zirconium-89- labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharm. 2016;7:1-15. [Crossref]  [PubMed]  [PMC]
  34. Pandit-Tasker N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal Sm, beylergil V, Lefkowitz RA, et al. A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015;12:5277-85. [Crossref]  [PubMed]  [PMC]
  35. Jauw YWS, Zijlstra Jm, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, van Dongen GAmS, et al.. Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to asses CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large b cell lymphoma. PLoS One. 2012;12:1-12. [Crossref]  [PubMed]  [PMC]
  36. Ghai A, Zheleznyak A, mixdorf m, O'Neal J, Ritchey J, Rettig m, et al. Development of 89ZrDFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. Eur J Nuc med mol Imag. 2020. [Crossref]  [PubMed]  [PMC]